Slide 1: Sisram Medical 2026 H1 Earnings Presentation
Sisram Medical 2026 H1 Earnings Presentation Stock Code: 1696.HK 1
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”) which have been prepared by Sisram Medical Ltd (the “Company”) do not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any
Slide 3: 2026 H1 Snapshot
2026 H1 Snapshot US$ 171.4M 56.7% 2.9% +3.6% YoY -3.3 p.p. YoY -4.3 p.p. YoY Gross Adjusted Net Profit Revenue Profit Margin Margin US$ 127.0M US$ 78.4M US$ 22.2M US$ 97.1M +16.7% YoY +19.1% YoY +54.2 % YoY +7.2 % YoY International Markets Revenue from Revenue from Revenue from (Excl. NA) APAC Injec
Slide 4: Strengthening Glocalization, Driving APAC Growth
Strengthening Glocalization, Driving APAC Growth Reinforcing our leadership across core and emerging markets, as we continue to scale globally with focus and agility Sustained APAC Growth UK DAC H North Europe America Korea China Japan Israel HK UAE India Thailand Africa Latin Americ Australia a Loc
Slide 5: EBD: Sustained Momentum, Accelerated Localization
EBD: Sustained Momentum, Accelerated Localization ü With a multi-year track record ü Successfully launched the ü Successfully launched “黑金牛奶 of strong sales, Alma Harmony Soprano Titanium in Thailand, 光” (Black Gold Photofacial) in continues to demonstrate gaining strong market reception Mainland Ch
Slide 6: Injectables: Rapid Growth, Differentiated Pipeline
Injectables: Rapid Growth, Differentiated Pipeline DAXXIFY Key Achievements ü 2026 H1: DAXXIFY achieved significant commercial milestones in Mainland China, leveraging its differentiated value proposition to penetrate the premium neurotoxin market and • First FDA approved true innovation in neuromod
Slide 7: Injectables: Rapid Growth, Differentiated Pipeline (Cont.)
Injectables: Rapid Growth, Differentiated Pipeline (Cont.) • Strong growth momentum in Thailand • Advancing combined treatment protocols with Soprano family products in Thailand, to unlock deeper synergies between the EBD and Injectables businesses • Secured exclusive distribution rights across mult
Slide 8: AI-Powered Ecosystem: Market Traction, Global Expansion
AI-Powered Ecosystem: Market Traction, Global Expansion Al-enabled diagnostics and personalized skincare solutions strengthening our holistic ecosystem A whole new diagnostic product segment has A first-of-its-kind, AI-powered personalized emerged via the introduction of Alma IQ skincare system • 20
Slide 9: Strategic Pipeline Development
Strategic Pipeline Development EBD Injectables AI-Powered Ecosystem Clinical-Stage Pipelines Silk Fibroin 9
Slide 10: Enhancing R&D and Innovation Capabilities
Enhancing R&D and Innovation Capabilities • Appointed a new Executive Vice President of R&D, bringing 20+ years of medical device R&D experience to strengthen technology development and commercialization capabilities • Optimized R&D organization and governance, enhancing resource allocation and cros
Slide 11: 2026 H2 Key Initiatives
2026 H2 Key Initiatives China Market • Advance DAXXIFY’s phased expansion in China by developing benchmark clinics, refining localized injection protocols, and driving increased utilization and repeat purchases • Accelerate sales of next-generation energy-based devices and unlock greater synergies b
Slide 12: Financial Review
Financial Review
Slide 13: 2026 H1 Financials
2026 H1 Financials • Revenue increased by 3.6% YoY in 2026 H1. Notably, 2026 Q2 revenue recorded a strong increase on both a year-on-year and a quarter-on-quarter basis. Revenue from international markets (excluding North America) increased by 16.7% YoY, while revenue from APAC up 19.1% YoY, driven
Slide 14: 2026 H1 Financials: Revenue Breakdown by Geography
Latin America Europe 2026 H1 Middle East and Africa 3.0% 15.6% North America 56,597 44,389 9.8% Financials APAC 65,825 78,407 23,827 Europe 26,708 Middle East and 13,910 Revenue Breakdown Africa 16,817 by Geography North Latin America 5,317 5,102 APAC America 25.9% 2025 H1 2026 H1 US$ thousand 45.7%
Slide 15: 2026 H1 Financials: Revenue by Segments and Products
• Medical Aesthetics products, led by flagship platforms including Harmony, 2026 H1 Soprano, Hybrid, Accent and Opus contributed for 78.4% of total revenue, with sales of US$134.3 million, decreased by 2.5% YoY, primarily effected by the softer performance in North America Financials • Medical Aesth
Slide 16: 2026 H1 Financials OPEX Analysis
2026 H1 Financials OPEX Analysis • Adopted prudent financial practices to enhance operational efficiency across mature direct offices, demonstrating agility in adjusting the OPEX structure in response to market fluctuations • The YoY increase of 8.5% in operating expenses was primarily driven by con
Slide 17: Appendix
Appendix
Slide 18: Advancing Sisram's Consumer-Centric Beauty and Wellness Ecosystem
Advancing Sisram’s Consumer-Centric Beauty and Wellness Ecosystem Through synergistic business segments Our Mission Empowering aesthetics practitioners with state-of-the-art, clinically proven, holistic wellness solutions - spanning energy- based devices, injectables, diagnostic platforms and AI-ass
Slide 19: Comprehensive Product and Service Solutions Across Key Aesthetics Segments
Comprehensive Product and Service Solutions Across Key Aesthetics Segments Core Business B2B2C Key Development B2B2C Offer skin boosters, dermal fillers and a A world leading provider of medical aesthetics energy-based device next-generation botulinum toxins AI-Enabled Complementary Solutions Profhi
Slide 20: EBD Product Portfolio
EBD Product Portfolio Body BeautiFill by LipoLife Alma PrimeX Accent Alma Prime PrimeX Skin Alma Harmony Opus Alma Hybrid ALMA Q Pixel CO 2 Derma REJUVE Clear 20
Slide 21: EBD Product Portfolio (Cont.)
EBD Product Portfolio (Cont.) Hair Soprano Titanium Alma TED Soprano SE +20% power Alma Duo FemiLift Sexual Wellness 21
Slide 22: Injectables Product Portfolio
Injectables Product Portfolio Building on extensive clinical experience with energy-based devices, Sisram is strengthening the synergy between EBD and injectables—offering professional customers a unique combination of treatment modalities that delivers enhanced aesthetics outcomes and a superior co
Slide 23: Sisram Medical 1696.HK
As of 30th June 2026 Fosun Pharma Public 2196.HK Shareholders 600196.SH 71.42% 28.58% Sisram Medical 1696.HK 100% 23